目录产品 » LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human
Manual
SDS
COAs

LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human

LILRA1, also known as CD85i and LIR-6, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA1 consists of a 445 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 7 aa cytoplasmic tail. LILRA1 may act as receptor for class I MHC antigens.
￥5800
Z04536

产品简介
Species Human
Protein Construction
LILRA1/CD85i/LIR-6 (Pro17-Asn461)
Accession # O75019-1		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 0.1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 51.4 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
查看更多
返回

技术背景
Target Background LILRA1, also known as CD85i and LIR-6, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA1 consists of a 445 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 7 aa cytoplasmic tail. LILRA1 may act as receptor for class I MHC antigens.
Synonyms CD85i; LILRA1; LIR6; LIR-6; LIR6MGC126563
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.